In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 659 ( 2022-08-24)
Abstract:
Genetically attenuated malaria parasite vaccines are currently being developed as candidates for protection against Plasmodium falciparum infection. Murphy et al. used a genetically attenuated P. falciparum sporozoite vaccine they had previously developed that has deletions in parasite genes P52 , P36, and SAP1 (PfGAP3KO) to evaluate protection against controlled human malaria infection (CHMI). Vaccine was administered three or five times by ~200 PfGAP3KO-infected mosquito bites per immunization and did not cause any breakthrough infections. CHMI challenge was carried out 1 month after final immunization via P. falciparum –infected mosquito bites. Half of the individuals in each vaccine group did not develop detectable P. falciparum infection, and a subset of these individuals was subjected to a second CHMI 6 months later and remained partially protected. These results support further development of genetically attenuated sporozoites as potential malaria vaccines.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abn9709
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink